Intervention not reported
Respiratory outcomes: FEV1 (% predicted): · children and adults with CF
1 finding from 1 review
Intervention not reported
Pulmonary function test (FVC) % predicted · infants and young children with cystic fibrosis
The intervention showed no clear difference in pulmonary function test (FVC) % predicted (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in lung function ‐ FEV₁ (% predicted): at 12 months · adults and children with cystic fibrosis
1 finding from 1 review
Participant satisfaction (very satisfied or satisfied) · people with transfusion‐dependent thalassemia
Deferasirox probably leads to higher satisfaction with treatment (very satisfied or satisfied):… compared with deferoxamine (moderate certainty).
1 finding from 1 review
Other measures of lung function: mean change from baseline in FEV1 AUC0-4h (% predicted) after tiotropium 5.0 µg · adults and children with cystic fibrosis
1 finding from 1 review
Change in baseline trough FEV1 · adults and children with cystic fibrosis
1 finding from 1 review
Intervention not reported
Depression standardised depression scores · patients with sickle cell disease
1 finding from 1 review
FEV1 · children with chronic disease
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Stroke · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
Long‐term red cell transfusion probably leads to lower clinical stroke compared with no transfusion (moderate certainty).
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
TIA · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Serious adverse events as a result of sickle cell‐related complications · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Measures of neurological impairment ‐ not reported · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stroke · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review